ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors

177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).